109
Participants
Start Date
December 21, 2017
Primary Completion Date
July 28, 2021
Study Completion Date
July 28, 2021
JBT-101
Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Placebo
Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
New York University Langone Medical Center: Department of Medicine, Division of Rheumatology, New York
Columbia University Medical Center: Department of Medicine, Division of Rheumatology, New York
Bronx-Lebanon Hospital Center: Division of Rheumatology, The Bronx
Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases, Manhasset
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh
Penn State MS Hershey Medical Center, Hershey
University of Pennsylvania, Philadelphia
Temple University, Philadelphia
Duke University, Durham
Medical University of South Carolina, Charleston
Emory University: Division of Rheumatology, Atlanta
MetroHealth Medical Center, Cleveland
UCLA Medical Center: Division of Rheumatology, Los Angeles
University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology, La Jolla
University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center, San Francisco
Yale University, New Haven
Collaborators (1)
Corbus Pharmaceuticals Inc.
INDUSTRY
Autoimmunity Centers of Excellence
OTHER
Rho Federal Systems Division, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH